ArticleJournal of thoracic disease2025
Construction and identification of a prognostic and therapeutic signature based on ferroptosis-related oxidative stress genes in lung adenocarcinoma.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the leading cause of cancer-associated deaths globally, with lung adenocarcinoma (LUAD) being the predominant type. Ferroptosis, a unique form of iron-dependent programmed cell death that results from lipid peroxidation, plays a critical role in the initiation and progression of LUAD. In this study, we aimed to construct and identify an effective prognostic model that could serve as a potential therapeutic target for LUAD. Methods: The expression of ferroptosis-related genes obtained from FerrDb and oxidative stress-related genes collected from MSigDB were analyzed using data from The Cancer Genome Atlas-LUAD cohort. Least absolute shrinkage and selection operator Cox regression, CoxBoost, random survival forest, and stepwise Cox analyses were performed to screen for suitable gene signatures for modeling. Finally, we developed and verified a novel ferroptosis-and oxidative stress-related risk model. Results: An 11-gene-based prognostic model, comprising Conclusions: We established a novel ferroptosis-related oxidative stress gene-related model that possesses potential predictive value for prognosis of patients with LUAD, immunotherapy response, and chemotherapeutic drug sensitivity, and indicated its potential applicability in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.